![1,2,4-triazole derivative with Schiff base; thiol-thione tautomerism, DFT study and antileishmanial activity - ScienceDirect 1,2,4-triazole derivative with Schiff base; thiol-thione tautomerism, DFT study and antileishmanial activity - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022286017311444-egi10RTBS1ZT82.jpg)
1,2,4-triazole derivative with Schiff base; thiol-thione tautomerism, DFT study and antileishmanial activity - ScienceDirect
![PDF) Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial PDF) Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial](https://i1.rgstatic.net/publication/325543229_Everolimus_Plus_Exemestane_vs_Everolimus_or_Capecitabine_Monotherapy_for_Estrogen_Receptor-Positive_HER2-Negative_Advanced_Breast_Cancer_The_BOLERO-6_Randomized_Clinical_Trial/links/5b6cd5f545851546c9f95b3b/largepreview.png)
PDF) Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial
![PDF) Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial PDF) Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial](https://i1.rgstatic.net/publication/301938314_Pictilisib_for_oestrogen_receptor-positive_aromatase_inhibitor-resistant_advanced_or_metastatic_breast_cancer_FERGI_A_randomised_double-blind_placebo-controlled_phase_2_trial/links/5ae85170a6fdcc03cd8e1066/largepreview.png)
PDF) Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial
![Un pilote de Strike Eagle F-15E de la Force aérienne des États-Unis affecté au 391st Fighter Squadron, à la base aérienne de Mountain Home, en Idaho, participe à un exercice Inject lors Un pilote de Strike Eagle F-15E de la Force aérienne des États-Unis affecté au 391st Fighter Squadron, à la base aérienne de Mountain Home, en Idaho, participe à un exercice Inject lors](https://c8.alamy.com/compfr/2jb3xwe/un-pilote-de-strike-eagle-f-15e-de-la-force-aerienne-des-etats-unis-affecte-au-391st-fighter-squadron-a-la-base-aerienne-de-mountain-home-en-idaho-participe-a-un-exercice-inject-lors-de-raging-gunfighter-22-2-a-l-aerodrome-de-wendover-a-wendover-en-utah-le-21-mai-2022-l-aerodrome-de-wendover-a-ete-utilise-comme-lieu-d-entrainement-pour-les-equipages-b-17-b-24-et-b-29-pendant-la-seconde-guerre-mondiale-et-sert-une-combinaison-d-utilisations-civiles-et-militaires-aujourd-hui-e-u-photo-de-la-force-aerienne-par-le-senior-airman-cole-yardley-2jb3xwe.jpg)